Pegylated L-Asparaginase

Phase 3Protein / enzyme

Pegylated L-Asparaginase is one of 26 small molecule programs targeting B Acute Lymphoblastic Leukemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

B Acute Lymphoblastic LeukemiaRecruiting

B Acute Lymphoblastic LeukemiaPhase 3

Recruiting

Competition

Competitive Landscape

26 competitors in B Acute Lymphoblastic Leukemia

#DrugCompanyPhaseTrials

Cytosar

Teva

Phase 3

5 2

Trexall

Jazz Pharmaceuticals

Phase 3

5 3

Oncovin

Eli Lilly

Phase 3

3 4

Adriamycin

Pfizer

Phase 3

3 5

Blincyto

Amgen

Phase 3

3 6

Adriamycin

Pfizer

Phase 3

2 7

Rituxan

Roche

Phase 3

2 8

Zyloprim

Jazz Pharmaceuticals

Phase 3

1 9

Cytoxan

BBaxter Healthcare Corporation

Phase 3

7 10

Purinethol

SStason

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 3Recruiting

B Acute Lymphoblastic Leukemia

NCT03150693

Clinical

Trials by Indication[1]

ALS1 trial

Interferon Alpha 2b Intensification in HIV-Positive Individuals on Antiretroviral Therapy

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT01295515·7 enrolled

Intravenous1 trial

Peg-Interferon Alpha 2b Combined With Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-1074 (BEAT-2)

Unknown status·LLuis Montaner·Phase 1·NCT03588715·15 enrolled

Fallopian Tube Cancer1 trial

Phase II Study of Clinical Activity of Pegaspargase in Women With Relapsed or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01313078·4 enrolled

B Acute Lymphoblastic Leukemia1 trial

A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL

Recruiting·AAlliance for Clinical Trials in Oncology·Phase 3·NCT03150693·303 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Pegylated L-Asparaginase. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pegylated L-Asparaginase compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pegylated L-Asparaginase. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Phase 3[1]
Company: NNational Cancer Institute (NCI)

Pegylated L-Asparaginase

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

ALS1 trial

Intravenous1 trial

Fallopian Tube Cancer1 trial

B Acute Lymphoblastic Leukemia1 trial

References

Drug Info

Quick Facts

Related News